TITLE

Pfizer to jettison 10,000 workers

AUTHOR(S)
Chynoweth, Emma
PUB. DATE
January 2007
SOURCE
ICIS Chemical Business;1/29/2007, Vol. 2 Issue 51, p17
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article announces a programme planned by Pfizer to maximise near- and long-term revenues from its current products and through external alliances. Pfizer chairman and chief executive officer Jeffrey Kindler said that the company Hill continue to invest in research and development, business development, emerging markets and new marketing approaches.
ACCESSION #
23977802

 

Related Articles

  • Modern Medicine Man. Kindler, Jeff // Newsweek (Pacific Edition);4/9/2007 (Pacific Edition), Vol. 149 Issue 15, p58 

    The article presents excerpts from an interview with Jeff Kindler, appointed as chief executive officer of Pfizer in 2006. Kindler discusses his feeling that the pharmaceutical industry has not done a good job communicating how it helps the public or why its marketing costs are so high. He...

  • Good Counsel. Kindler, Jeffrey // Pharmaceutical Executive;Jul2006, Vol. 26 Issue 7, p42 

    The article introduces Jeffrey Kindler, a legal counsel of Pfizer company. Kindler was chosen for the job because he was considered as the best general counsel, not to mention his educational background. A graduate from Harvard Law School, he then clerked for two judges, including U.S. Supreme...

  • Pfizer Promotes Kindler to CEO. Nicholas, Adele // InsideCounsel;Sep2006, Vol. 16 Issue 178, p16 

    The article reports the promotion of general counsel Jeffrey Kindler as CEO of Pfizer on July 28, 2006. The reason behind his promotion is cited. It presents information on the career background of Kindler.

  • Pfizer Reports Third-Quarter 2011 Results.  // Biomedical Market Newsletter;11/7/2011, Vol. 21, p803 

    The article reports on the financial statements of New York City-based Pfizer Inc. for the third quarter ended September 30, 2011. It says that the company's worldwide revenues increased by 7.0% to 17.2 billion dollars, but its U.S. revenues declined by 3.0%. It also notes the profits from the...

  • Pfizer revenues climb despite stable drug prices.  // hfm (Healthcare Financial Management);Sep98, Vol. 52 Issue 9, p22 

    Reports on the financial performance of American pharmaceutical company Pfizer Inc. in the second quarter of 1998. Revenue increase; Net income; Record sales of the company's male impotence remedy Viagra; Prescription drug prices in the United States.

  • Pfizer has top pharmaceutical sales force.  // Medical Marketing & Media;Mar2001, Vol. 36 Issue 3, p22 

    Reports on the increase sales of Pfizer Inc. in the U.S.

  • Pfizer Reports Higher Profits and Share Buyback Plan.  // MondayMorning;11/7/2011, Vol. 19 Issue 40, p1 

    The article provides information on profits and share buyback plan of pharmaceutical firm Pfizer Inc. It states that the third quarter revenue was around 17.2 billion U.S. dollars as compared to previous year results. Ian C. Read, chief executive officer of the company has increased spending on...

  • Closure of Pfizer Sandwich. Kaplan, Claude // Applied Clinical Trials;May2011, Vol. 20 Issue 5, p19 

    The article reports that the closure of Pfizer Inc., a pharmaceutical research company, has indicated the loss of faith on the research & development industry (R & D) in Sandwich, England.

  • Pfizer Announces Updated, Interactive Development Pipeline.  // Biomedical Market Newsletter;3/21/2011, p125 

    The article reports that Pfizer Inc. has provided an update of its development pipeline that includes an overview of its research and list of compounds in development with directed indication.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics